aXichem (AXIC A) Stock Overview
A biotechnology company, engages in the development of natural analogue ingredients in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
AXIC A Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
aXichem AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 2.38 |
| 52 Week High | SEK 4.10 |
| 52 Week Low | SEK 0.97 |
| Beta | -0.23 |
| 1 Month Change | -10.19% |
| 3 Month Change | -40.50% |
| 1 Year Change | 65.28% |
| 3 Year Change | -83.12% |
| 5 Year Change | -94.97% |
| Change since IPO | -85.98% |
Recent News & Updates
Recent updates
Is aXichem (STO:AXIC A) In A Good Position To Invest In Growth?
Aug 23
aXichem (STO:AXIC A) Is Carrying A Fair Bit Of Debt
Jun 10aXichem (STO:AXIC A) Is In A Good Position To Deliver On Growth Plans
Sep 04Here's Why We're Watching aXichem's (STO:AXIC A) Cash Burn Situation
Apr 01We Think aXichem (STO:AXIC A) Needs To Drive Business Growth Carefully
Dec 17Shareholder Returns
| AXIC A | SE Chemicals | SE Market | |
|---|---|---|---|
| 7D | -2.5% | 1.1% | 2.3% |
| 1Y | 65.3% | -19.8% | 3.2% |
Return vs Industry: AXIC A exceeded the Swedish Chemicals industry which returned -19.1% over the past year.
Return vs Market: AXIC A exceeded the Swedish Market which returned 4.1% over the past year.
Price Volatility
| AXIC A volatility | |
|---|---|
| AXIC A Average Weekly Movement | 9.0% |
| Chemicals Industry Average Movement | 8.1% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: AXIC A's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: AXIC A's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 7 | Torsten Helsing | www.axichem.com |
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings and underground cables; and aXiphen-feed, a solution for enhanced health for chickens, hens, pigs, and piglets. The company was founded in 1999 and is based in Malmö, Sweden.
aXichem AB Fundamentals Summary
| AXIC A fundamental statistics | |
|---|---|
| Market cap | SEK 140.69m |
| Earnings (TTM) | -SEK 17.67m |
| Revenue (TTM) | SEK 15.88m |
Is AXIC A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXIC A income statement (TTM) | |
|---|---|
| Revenue | SEK 15.88m |
| Cost of Revenue | SEK 6.87m |
| Gross Profit | SEK 9.00m |
| Other Expenses | SEK 26.68m |
| Earnings | -SEK 17.67m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 26, 2026
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 56.72% |
| Net Profit Margin | -111.32% |
| Debt/Equity Ratio | 4.0% |
How did AXIC A perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/01 11:28 |
| End of Day Share Price | 2025/11/28 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
aXichem AB is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Johan Svantesson | Redeye |